Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 248-368-3 | CAS number: 27253-26-5
Toxicological Summary
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 44.08 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 6
- Modified dose descriptor starting point:
- NOAEC
Acute/short term exposure
DNEL related information
Local effects
Acute/short term exposure
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 312.5 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 24
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
DNEL related information
Workers - Hazard for the eyes
Additional information - workers
- Although "residual" interspecies variability may remain following allometric scaling, this is largely accounted for in the default assessment factor proposed for intraspecies variability.
- Following analysis of the inherent variability in human toxicokinetic and toxicodynamic parameters, a difference of 3 (close to the 90th percentile) was considered appropriate to account for variability present in worker groups while a value of 5 (equivalent to the 95th percentile) was appropriate for the general population.
The REACH Technical Guidance Document R.8 contains default assessment factors which should be applied to a modified dose descriptor in order to obtain a DNEL. These factors are multiplicative and can lead to a human chronic NAEL that is 100 or 200 fold lower than the equivalent rat subchronic NOAEL. However other guidance is available from ECETOC (2003), which supports smaller assessment factors to account for inter- and intra- species differences; leading to a human chronic NAEL that is only 24 to 40 -fold lower than an equivalent rat subchronic NOAEL.
The ECETOC technical report includes scientific justification for the magnitude of these assessment factors, including:
Section R.8.4.3.3 of the REACH Technical Guidance Document recognizes that the overall assessment factor applied to an experimental NOAEL when developing a DNEL is multiplicative in nature, and that "Care should be taken to avoid double counting several aspects when multiplying the individual factors." Based on the information presented in ECETOC (2003) and summarized above, use of the standard defaults for inter- and intra- species variability contained in REACH Technical Guidance Document appears to result in "double counting", and if used inappropriately, would lead to a large, conservative overall assessment factor.
In order to retain the scientific credibility in its DNEL setting process, we will adopt the assessment factors proposed by ECETOC (2003) when developing DNELs.
Acute toxicity
A DNEL for acute toxicity should be derived if an acute hazard leading to acute toxicity (e.g. C&L) has been identified and there is a potential for high peak exposures. These "peaks" are normally associated with inhalation exposure but are less common for skin contact and ingestion (Appendix R.8-8). DTDP is not classified for acute toxicity; oral, dermal or inhalation. It does not present an acute hazard following skin and exposure via the oral route is not relevant for workers.
Irritation
DTDP is not classified as an irritant and does not require the derivation of a DNEL for this endpoint.
Long-term systemic effects
The potential of a substance to cause long-term systemic effects can
judged based on the results of repeated dose toxicity testing. The
following DNELs are conservative by nature and are protective of all
adverse effects; such as carcinogenicity and reproductive/developmental
effects.
For DTDP, the following NOAEC, presented in the IUCLID dossier, is
deemed to be substantially protective of all potential adverse effects.
Oral:
subchronic effects for DIDP: rat NOAEL = 150 mg/kg bw/d
Inhalation (no systemic effects):
route-to-route extrapolation from oral NOAEL
Dermal (no systemic effects):
route-to-route extrapolation from oral NOAEL
Dermal
DTDP, like other high molecular weight phthalates, is anticipated to have a very low dermal penetration rate (2-4%). While a repeated dose dermal study is available for DINP, it is not suitable for DNEL calculation due to several study limitations; it is an old study (1969) performed prior to GLP, a small number of animals were used (n=4 per group where 2 were abraded and 2 were not), there was an in-house infection in which animals in the control and treated groups died and the others required pharmacological intervention, an incomplete histopathological analysis was performed (only liver, kidney, and skin were examined).
A dermal DNEL will be calculated from route to route extrapolation from the rat oral NOAEL of 150 mg/kg/day. This value is expected to be protective since there are clear dose responses via the oral route of exposure and it is highly unlikely that enough material could be applied to animals, since the dermal penetration rate is so low (2%), to observe similar effects.
Dose descriptor
rat oral NOAEL = 150 mg/kg/day.
Assumptions
100% oral absorption regardless of species
2% dermal absorption regardless of species
Modification of dose descriptor
Route-to-route extrapolation (calculation B.5 in ECHA Guidance R.8):
dermal NOAEL = oral NOAEL * (ABS oral / ABS dermal)
dermal NOAEL = 150 mg/kg/day * (100/2)
dermal NOAEL = 7500 mg/kg/day
Assessment factors ¿ Based on ECETOC guidance document #86
Uncertainty |
AF |
Justification |
Allometric scaling |
4 |
default for the rat |
Subchronic study |
2 |
subchronic to chronic extrapolation |
Intraspecies differences |
3 |
default AF for workers |
Overall AF |
24 |
|
DNEL worker dermal= 7500 mg/kg bwt/d / 24
= 312.50 mg/kg bwt/d
Inhalation
Due to its extremely low vapour pressure, DTDP vapour phase concentrations are unlikely to attain high levels, even at high temperatures used in some industrial conditions. At high temperatures and mechanical pressures, aerosol formation is expected with DTDP like with other phthalates. Exposure to aerosol is therefore possible in any situation where pure DTDP is heated or materials containing DTDP are heated under influence of mechanical pressure. Exposure to DTDP aerosol is likely to result in limited absorption through the lungs and is more likely to result in oral absorption due to mucocilliary clearance. The protective value used to calculate and inhalation DNEL is derived from the oral NOAEL 150 mg/kg/day as opposed to the data presented in the 2-week repeated dose study with aerosolized DIDP in which the limit dose was tested and no systemic effects were reported.
Dose descriptor
rat oral NOAEL = 150 mg/kg/day
Assumptions
100% oral absorption regardless of species
100% inhalation absorption regardless of species
Modification of dose descriptor calculation B.3 in ECHA Guidance R.8
inhalatory NOAEC = oral NOAEL * (1/ sRV rat 8h) * (ABS oral / ABS inh) * (sRV human / wRV)
inhalatory NOAEC= 150 * (1/0.38) * (100/100) * (6.7 / 10)
inhalatory NOAEC = 264.47 mg/m3
Assessment factors - Based on ECETOC guidance document #86
Uncertainty |
AF |
Justification |
subchronic study |
2 |
subchronic study |
workers |
3 |
default workers |
Overall AF |
6 |
|
DNEL worker inhalation = 264.47 mg/m3/ 6
= 44.08 mg/m3
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 13.04 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 10
Acute/short term exposure
DNEL related information
Local effects
Acute/short term exposure
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 187.5 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 40
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- DMEL (Derived Minimum Effect Level)
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 3.75 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 40
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
DNEL related information
General Population - Hazard for the eyes
Additional information - General Population
- Although ¿residual¿ interspecies variability may remain following allometric scaling, this is largely accounted for in the default assessment factor proposed for intraspecies variability.
- Following analysis of the inherent variability in human toxicokinetic and toxicodynamic parameters, a difference of 3 (close to the 90th percentile) was considered appropriate to account for variability present in worker groups while a value of 5 (equivalent to the 95th percentile) was appropriate for the general population.
The REACH Technical Guidance Document R.8 contains default assessment factors which should be applied to a modified dose descriptor in order to obtain a DNEL. These factors are multiplicative and can lead to a human chronic NAEL that is 100 or 200 fold lower than the equivalent rat subchronic NOAEL. However other guidance is available from ECETOC (2003), which supports smaller assessment factors to account for inter- and intra- species differences; leading to a human chronic NAEL that is only 24 to 40 -fold lower than an equivalent rat subchronic NOAEL.
The ECETOC technical report includes scientific justification for the magnitude of these assessment factors, including:
Section R.8.4.3.3 of the REACH Technical Guidance Document recognizes that the overall assessment factor applied to an experimental NOAEL when developing a DNEL is multiplicative in nature, and that "Care should be taken to avoid double counting several aspects when multiplying the individual factors." Based on the information presented in ECETOC (2003) and summarized above, use of the standard defaults for inter- and intra- species variability contained in REACH Technical Guidance Document appears to result in "double counting", and if used inappropriately, would lead to a large, conservative overall assessment factor.
In order to retain the scientific credibility in its DNEL setting process, we will adopt the assessment factors proposed by ECETOC (2003) when developing DNELs.
Acute toxicity
A DNEL for acute toxicity should be derived if an acute hazard leading to acute toxicity (e.g. C&L) has been identified and there is a potential for high peak exposures. These "peaks" are normally associated with inhalation exposure but are less common for skin contact and ingestion (Appendix R.8-8). DTDP is not classified for acute toxicity; oral, dermal or inhalation. It does not present an acute hazard following skin and exposure via the oral route is not relevant for workers.
Irritation
DTDP is not classified as an irritant and does not require the derivation of a DNEL for this endpoint.
Long-term systemic effects
The potential of a substance to cause long-term systemic effects can
judged based on the results of repeated dose toxicity testing. The
following DNELs are conservative by nature and are protective of all
adverse effects; such as carcinogenicity and reproductive/developmental
effects.
For DTDP, the following NOAEC, presented in the IUCLID dossier, is
deemed to be substantially protective of all potential adverse effects.
Oral:
subchronic effects for DIDP: rat NOAEL = 150 mg/kg bw/d
Inhalation (no systemic effects):
route-to-route extrapolation from oral NOAEL
Dermal (no systemic effects):
route-to-route extrapolation from oral NOAEL
Inhalation
Due to its extremely low vapour pressure, DTDP vapour phase concentrations are unlikely to attain high levels, even at high temperatures used in some industrial conditions. At high temperatures and mechanical pressures, aerosol formation is expected with DTDP like with other phthalates. Exposure to aerosol is therefore possible in any situation where pure DTDP is heated or materials containing DTDP are heated under influence of mechanical pressure. Exposure to DTDP aerosol is likely to result in limited absorption through the lungs and is more likely to result in oral absorption due to mucocilliary clearance. The protective value used to calculate and inhalation DNEL is derived from the oral NOAEL 150 mg/kg/day as opposed to the data presented in the 2-week repeated dose study with aerosolized DIDP in which the limit dose was tested and no systemic effects were reported.
Dose descriptor
rat oral NOAEL = 150 mg/kg/day
Assumptions
100% oral absorption regardless of species
100% inhalation absorption regardless of species
Modification of dose descriptor calculation B.3 in ECHA Guidance R.8
inhalatory NOAEC = oral NOAEL * (1/ sRV rat 24h) * (ABS oral / ABS inh)
inhalatory NOAEC= 150 * (1/1.15) * (100/100) * (6.7 / 10)
inhalatory NOAEC = 130.43 mg/m3
Assessment factors - based on ECETOC Guidance document #86
Uncertainty |
AF |
Justification |
subchronic study |
2 |
subchronic to chronic extrapolation |
workers |
5 |
default population |
Overall AF |
10 |
|
DNELpopulation inhalation = 130.43 mg/m3/ 10
= 13.04 mg/m3
Oral
Dose descriptor
rat oral NOAEL = 150 mg/kg/day
Modification of dose descriptor
No modification is required (daily dosing)
Assessment factors - Based on ECETOC guidance document #86
Uncertainty |
AF |
Justification |
subchronic study |
2 |
subchronic to chronic extrapolation |
Interspecies differences |
4 |
default for rat |
Intraspecies differences |
5 |
default AF for general population |
Overall AF |
40 |
|
DNEL population oral = 150 mg/kg bwt/d / 40
= 3.75 mg/kg bwt/d
Dermal
DTDP, like other high molecular weight phthalates, is anticipated to have a very low dermal penetration rate (2-4%). While a repeated dose dermal study is available for DINP, it is not suitable for DNEL calculation due to several study limitations; it is an old study (1969) performed prior to GLP, a small number of animals were used (n=4 per group where 2 were abraded and 2 were not), there was an in-house infection in which animals in the control and treated groups died and the others required pharmacological intervention, an incomplete histopathological analysis was performed (only liver, kidney, and skin were examined).
A dermal DNEL will be calculated from route to route extrapolation from the rat oral NOAEL of 150 mg/kg/day. This value is expected to be protective since there are clear dose responses via the oral route of exposure and it is highly unlikely that enough material could be applied to animals, since the dermal penetration rate is so low (2%), to observe similar effects.
Dose descriptor
rat oral NOAEL = 150 mg/kg/day.
Assumptions
100% oral absorption regardless of species
2% dermal absorption regardless of species
Modification of dose descriptor
Route-to-route extrapolation (calculation B.5 in ECHA Guidance R.8):
dermal NOAEL = oral NOAEL * (ABS oral / ABS dermal)
dermal NOAEL = 150 mg/kg/day * (100/2)
dermal NOAEL = 7500 mg/kg/day
Assessment factors - Based on ECETOC guidance document #86
Uncertainty |
AF |
Justification |
Allometric scaling |
4 |
default for the rat |
Subchronic study |
2 |
subchronic to chronic extrapolation |
Intraspecies differences |
5 |
default AF for population |
Overall AF |
40 |
|
DNEL population dermal = 7500 mg/kg bwt/d / 40
= 187.50 mg/kg bwt/d
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
